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Abstract: Various 2-amin•-3-acy•-6-[(E)-•-pheny•-2-N-methy•carbam•y•viny•]-imidaz•[••2-a]pyridines• 
structurally related to Enviroxime were prepared to determine the effect of acyl groups on the anti- 
rhinoviral activity. A short and efficient means for the construction of the imidazo nucleus as well as 
biological evaluation of the final compounds are disclosed. © 1999 Elsevier Science Ltd. All rights reserved. 
Enviroxime I and related benzimidazoles 2'3 howed potent broad spectrum antiviral activity against 
a range of both rhinoviruses and enteroviruses. Noncytotoxic concentrations of Enviroxime are associated 
with complete inhibition of replication of 81 rhinovirus erotypes. However, studies of oral Enviroxime 
showed low levels in blood and nasal secretions and an unacceptably high frequency of nausea nd 
vomiting: Thus, despite its potent in vitro anti-rhinovirus activity, significant therapeutic benefit was not 
found with either oral or intranasal administration, and Enviroxime clinical studies were terminated. 
Despite this failure, considerable efforts are still devoted to the benzimidazole family with the aim of 
finding an antirhinoviral nalogue with improved oral plasma levels and better safety profile: 
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As part of our ongoing program directed to the identification of non-benzimidazole structurally 
related analogues to Enviroxime, we have recently reported that 2-amino-6-[(E)-l-phenyl-2-N- 
methylcarbamoylvinyl]-imidazo[l,2-a]pyridines 6 can maintain the anti-rhinoviral activity found in 
benzimidazoles. In this new family the substitution at3-position was a key element for activity and both 
isopropyl sulfenyl and aromatic tings were well tolerated. 
In a recent report, Spitzer et a/2'3 provided strong evidence for internal hydrogen bonding between 
the amine hydrogen and the sulfonyl oxygen which could account for the high potency exhibited by the 
Enviroxime. Acyl groups that would be expected to participate in the internal hydrogen-bond in an 
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analogous way as sulfonyl groups, were not investigated in the benzimidazole series because of their 
chemical instability. Herein we wish to report that the structurally related analogues, imidazo[1,2-a] 
pyridines la-d, may overcome the SAR limitation of benzimidazoles in terms of stability and synthetic 
flexibility. In the present case it made possible an investigation of the effect of acyl groups in a critical 
region of the molecule. 
Our synthetic approach to the desired imidazo[1,2-a]pyridines envisioned incorporation of vinyl 
carboxamide followed by an alkylation with chloro or bromo ketones. The use of the one step procedure 
that we previously described for the generation of 2-aminoimidazo moiety from the corresponding 2-
chloropyridinium salts (or ylides) would allow a direct access to our target structures. 7 
To this end, compound 2, 8 was subjected to the Homer-Emmons reaction with diethyl(N- 
methylcarbamoyimethyl)phosphonate, using KHMDS as a base in DMF, to give the key intermediate 
vinyl carboxamide 4 as 3:1 mixture of E and Z isomers. 9 The desired E-isomer 4 ]o was obtained in its 
pure form after a column chromatography. 
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Reaction of 2-chloro-5 -(1-phenyl-2-N-methylcarbamoylvinyl)pyridine (E)-4 with the 
commercially available chloroketone 5b,c or bromoketone 5a,d, under refluxing acetonitrile in the 
presence of NaI, afforded in three cases the corresponding heterobetaines 6b (85% yield), 6e (67%) and 
6d (46%) and only in one case the pyridinium salt 6a (60%). Interestingly the presence of N- 
methylcarbamoylvinyl function in this substrate facilitates the alkylation process and there was no need 
for the microwave assistance as in the examples that we have previously reported. 7 Finally, our one-step 
procedure 7 for the generation of 2-aminoimidazo moiety was applied successfully for the completion of 
our target molecules. Thus, treatment of substrates 6a-d with cyanamide in presence of K2CO3 in 
refluxing acetonitrile, furnished irectly the corresponding 2-aminoimidazo[1,2-a]pyridines la-d. It is 
most likely that the cyanamide acts as a nucleophile that displaces the chlorine on pyridinium salt 6a or 
ylides 6b-d to form an intermediate (Scheme 1) that cyclizes under basic conditions. Importantly, in the 
case of ylides 6b-d only 1 eq. of K2CO3 was needed, while in the case of pyridinium salt 6a, 2 eq. of base 
were required for the complete conversion. This conversion is notable in that it affords the desired 2- 
amino imidazo[1,2-a]pyridine derivatives in one-step, which is to our knowledge the shortest known 
method for the access to this type of nucleus. 
The final imidazo[1,2-a]pyridines la-d were subjected to biological evaluation taking Enviroxime 
as a reference. Human rhinovirus-14 was selected as the routine and initial virus for testing due to the 
amount of information known about his serotype. The plaque reduction assays (PRA) were run in order 
to determine the antiviral activity IC50 and the cytopathic effect assays (CPE/XTr) were performed as 
described previously 11in order to determine the general cellular toxicity TCs0 (Table 1). 
Table 1. Anti-Rhinoviral Activity (ICso) and Cellular Toxicity (TCs0) of 
Imidazopyridines la-d. 
Compds R ICs0(Ixg/mL) TCs0(Ixg/mL) 
PRA a CPE/XTT b 
Dihed. Angle c
(C2,C3,CO,O) 
la Me 2.48 22.8 -1.7 
lb Ph 0.24 2.95 19.7 
lc 4-F-Ph 0.37 3.97 20.2 
ld t-Bu 0.17 >10 45.2 
Plaque reduction assay using HRV- 14; Enviroxime used as reference (ICs0 = 0.045 Ixg/mL). 
b CPE/XTT assay using HRV-14. cDihedral ngles, calculated with AM1 hamiltonian. 
An acetyl group at 3-position afforded a compound with moderate antiviral activity. Interestingly 
t-butylacetyl atthe same position provided a compound with an ICs0(~g/mL) of 0.17 in PRA assay, 15- 
fold more active than the methyl partner. A benzoyl substituent a C(3) also provided apotent compound. 
A substitutent in para-position such as fluorine on the C(3) aryl was well-tolerated, providing a 
compound that maintained the activity. The biological data suggested that the antiviral activity is 
depending on the size of the group at C-3 and increases in the order methyl<aryl< t-butyl. However, the 
presence of an oxygen (C=O) that may participate in internal hydrogen bonding with the amine hydrogen 
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does not seem to be critical to anti-rhinoviral ctivity as in the case of Enviroxime, 2 since the activity 
observed in the examples lb  and lc is in the same order as that exhibited by their aryi partners. 6 
In order to help understanding the role of the size of the group at C-3 on the activity, we carded 
out semi-empirical calculations. Compound la-d were studied using AM1 hamiltonian. The 
conformational profiles calculated for each structure xhibit minima that differ mostly in the dihedral 
angle around the carbonyl at C-3 (C2,C3,CO,O). The geometrical feature of this angle seems to correlate 
with the activity in this class of compounds. Higher dihedral angle in ld (45 °) afforded acompound with 
potent antirhinoviral ctivity. On the other hand compound la with very small dihedral angle (-1.7 °) 
didn't show significant activity. 
Finally, compounds la-d were evaluated in a cytopathic effect assay in order to determine the 
general cellular toxicity TCs0. Compound ld seems to have quite high therapeutic ndex (ratio of TCs0 
over ICs0 is higher than 60). In general no apparent cellular toxicity was observed in this series of 
compounds. 
In summary, we have described an efficient approach to the synthesis of acyl substituted 
imidazo[ 1,2-a]pyridines, structurally related to Enviroxime. This study demonstrated that imidazopyridine 
nucleus not only maintains the anti-rhinoviral ctivity found in benzimidazole but also admits groups that 
are not tolerated in benzimidazoles. In the present case it allows to investigate he effect of acyl groups in 
a critical region of the molecule. Compounds lb, lc and ld exhibited strong anti-rhinoviral ctivity and 
no apparent cellular toxicity was found. 
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